Charles River announced the launch of its new online Tumor Model Compendium web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumor models based on specific molecular and histological properties, accompanied by selected patient information.
Charles River’s Compendium provides access to a collection of tumor models for early-stage oncology research. The collection includes tumor models from a wide range of tumor subtypes for both in vivo and in vitro oncology research, including patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models. These resources allow researchers to easily identify the most appropriate tumor models, leading to a more targeted study design from the start, saving time and money on the path to the clinic.
Dedication to Immuno-oncology
The most recent Compendium update expands existing content to include human leukocyte antigen (HLA) subtyping data. As the immuno-oncology industry shifts toward increasingly more personalized therapies, the availability of HLA data helps researchers understand and control immune system variability, leading to increased study efficacy and efficiency.
In Vitro Oncology Services
Additionally, the Compendium now includes new molecular data for a large proportion of its proprietary and commercial cell lines, making it a valuable resource for in vitro oncology research. In vitro oncology has emerged as an industry standard for early toxicity and patient identification, allowing researchers to test the efficacy of compound in a rapid, reliable, and cost-effective way.